ClinicalTrials.gg
RecruitingNCT07123454Lumi-NHLUpdated Nov 2, 2026

A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

A Phase 1/2 interventional study of AZD4512 and Surovatamig in B-cell Non-Hodgkin Lymphoma, sponsored by AstraZeneca. Recruiting at 23 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by AstraZeneca · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 1 month later.
Updated Nov 2, 2026Primary completion movedStudy completion moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
164
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies in Lymphoma, B-Cell by AstraZeneca — 7 open to participants now, 9 under way, 3 of them phase 3. Lymphoma, B-Cell · AstraZeneca.

Planned enrollment
8th of 13
164 · median 226
Started
2025
with 3 others
Phase 1/2
3 of 15
2 open now
Registered
12th of 15
by date

Among the 15 studies in Lymphoma, B-Cell by AstraZeneca, this one is the 8th largest by planned enrollment of the 13 interventional ones that give a count, is one of 4 that started in 2025, is one of 3 in phase 1/2, and was the 12th registered.

Lymphoma, B-Cell

886 studies on the registry are indexed under Lymphoma, B-Cell; 286 are open to participants now.

Browse Lymphoma, B-Cell studies →

Open to participants now

7 of the 15 studies in Lymphoma, B-Cell by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Who these studies take

Of the 208 Lymphoma, B-Cell studies recruiting now, 128 (62%) set no upper age limit and 60 (29%) stop at 75 or younger; 37 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Lymphoma, B-Cell by AstraZeneca, or all of them as a file.
02

Study summary

This is a phase I/II open-label, global multicenter study to evaluate the safety and efficacy of AZD4512 monotherapy or in combination with other anticancer agent(s), in participants with relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL).

Read the detailed description

Study D9890C00001 (Lumi-NHL) is a modular study designed to evaluate the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and efficacy of AZD4512 monotherapy or in combination with other anticancer agent(s), in participants with relapsed/refractory B-NHL. Module 1 aims to study AZD4512 monotherapy with participants in R/R B-NHL who have been exposed to at least 2 prior lines of therapy. Module 2 aims to study AZD4512 in combination with surovatamig in participants with relapsed or refractory LBCL.

03

Conditions studied

  • B-cell Non-Hodgkin Lymphoma

Keywords

  • AZD4512
  • Non-Hodgkin Lymphoma (NHL)
  • Relapsed/Refractory
04

Who can participate

The criteria were revised on the registry on Nov 2, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Core Inclusion Criteria

  • Eligible patients must be adults (≥18 years)
  • Additional criteria include by Lugano 2014, performance status ≤2, and adequate organ and bone marrow function (as specified by blood counts, cardiac , renal and hepatic parameters, and coagulation indices).

Module 1 Monotherapy Inclusion criteria

  • Documented confirmed diagnosis of B-cell non-Hodgkin lymphoma (B-NHL) as per World Health Organization (WHO) 2022 classification. In the dose escalation phase, any B-NHL subtype is allowed (excluding some subtypes), while the backfill phase restricts inclusion to defined subtypes: large B-cell lymphomas (as defined as Diffuse large B-cell lymphoma (DLBCL), Grade 3b Follicular lymphoma (FL), high-grade B-cell lymphoma (HGBCL) NOS, DLBCL/HGBCL with MYC and BCL2 rearrangements, primary mediastinal Large B-cell lymphoma, T-cell/histiocyte-rich LBCL, and transformed indolent lymphoma) and mantle cell lymphoma.
  • Patients with LBCL must have disease after at least two and lack additional standard options with established benefit. Additionally patients must have progressed after both anti CD20 and at least one systemic chemotherapy regimen, and have considered-or be ineligible for-CAR-T, T cell engager, and stem cell transplant modalities Participants with MCL must have previously received an anti-CD20 based therapy, and BTKi

Module 2 Surovatamig Combination Inclusion criteria

  • Documented histologically confirmed diagnosis of LBCL as defined as: DLBCL ( not otherwise specified), Grade 3b FL, DLBCL/high grade B-cell lymphoma with MYC and BCL2 rearrangements, High grade B-cell lymphoma (not other specified), Primary mediastinal LBCL, T-cell/histiocyte-rich LBCL, Transformations of indolent B-cell lymphoma.
  • Participants who have received previous CD19-directed therapy must have locally assessed confirmation (after completion of the CD19-directed therapy) to demonstrate presence of CD19 expression by immunohistochemistry or flow cytometry.
  • Patients must have relapsed or refractory disease after at least two prior lines of systemic therapy and lack additional standard options with established benefit. Additionally patients must have progressed after both anti-CD20 and at least one systemic chemotherapy regimen, and have considered-or be ineligible for-CAR-T, T cell engager, and stem cell transplant modalities

Core Exclusion Criteria

  • Active CNS involvement from their B-NHL. Exclusion also applies to those who have received CAR-T , within 6 months or T cell engager therapies within 90 days prior to C1D1, any drug or other systemic anticancer therapies (except low-dose , ≤10mg prednisone/day) within 21 days or 5 half-lives, and curative radiation within 14 days (localized palliative radiotherapy is allowed).
  • Other exclusions include: HSCT within 180 days (unless stable without active for ≥2 months), autologous HSCT within 90 days (unless resolved toxicities), major surgery within 28 days, use of strong inhibitors within 14 days or 5 half-lives before the dosing date, use of -prolonging agents within 5 half-lives before the dosing date, or other within two years. Patients with unresolved ≥ Grade 2 AEs from prior therapy (except specified tolerable conditions), serious uncontrolled medical conditions, active infection within 14 days, or history/suspicion of significant ILD/pneumonitis are also excluded.
  • Females who are pregnant or breastfeeding are not eligible.
  • Previous dosing with AZD4512

Module 1 Exclusion Criteria Patients are excluded if they have a diagnosis of post transplant lymphoproliferative disease, Richter's transformation, Burkitt's lymphoma, CLL/SLL, Waldenstrom Macroglobulinemia/ Lymphoplasmacytic Lymphoma

Module 2 Exclusion Criteria

Participants will be excluded if they have:

  • central nervous system (CNS) pathologies, including neurological, neurodegenerative, psychiatric, or other severe mental health conditions.
  • Active or prior CNS involvement related to disease.
  • Leukemic presentation of non-Hodgkin lymphoma (NHL), with circulating malignant lymphoid cells in peripheral blood.
  • A history of hemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS). • Prior Grade ≥3 cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS) following CAR T-cell or T-cell engager (TCE) therapy, or any unresolved CRS/ICANS.
  • Prior exposure to surovatamig.
  • Diagnosis of Richter's transformation
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
164 participants (estimated)

Study arms

  • Experimental
    Module 1: AZD4512 Monotherapy dose escalation + backfill

    In module 1, the efficacy and safety of AZD4512 will be evaluated in R/R B-NHL. Module 1 will consist of both dose escalation and pharmacodynamic/safety backfills which will be used to support MTD and/or optimal biological dose (OBD) selection.

    Drug: AZD4512

  • Experimental
    Module 2: AZD4512 in combination with surovatamig dose escalation + backfills

    Module 2 aims to evaluate the safety, tolerability, PK, PD, immunogenicity, and preliminary efficacy of AZD4512 combined with surovatamig in participants with relapsed or refractory LBCL. The module will consist of both: dose escalation and pharmacodynamics/safety backfills.

    Drug: AZD4512 · Drug: Surovatamig

Interventions

  • DrugAZD4512

    AZD4512 is an antibody-drug conjugate targeting cluster of differentiation 22 (CD22) that will be administered via IV infusion

  • Surovatamig (AZD0486) is a 'bispecific' antibody to be administered via IV infusion

06

What researchers measure

Primary outcomes

  1. Percentage of participants with dose-limiting toxicities (DLTs) during the DLT period

    To assess the safety and tolerability of AZD4512 monotherapy or in combination in participants with R/R B-NHL

    Time frame: Up to 4 weeks

  2. Frequency, duration, severity of Treatment-Emergent Adverse Events (TEAEs) and Treatment-Related Adverse Events (TRAEs) and Serious Adverse Events (SAEs)

    To assess the safety and tolerability of AZD4512 monotherapy or in combination in participants with R/R B-NHL

    Time frame: From the first dose up to and including 30 (+7) days after the last dose of study treatment , but prior to subsequent cancer therapy

  3. Frequency of SAEs/AEs leading to discontinuation of study treatment

    To assess the safety and tolerability of AZD4512 monotherapy or in combination in participants with R/R B-NHL

    Time frame: From the first dose up to and including 30 (+7) days after the last dose of study treatment , but prior to subsequent cancer therapy

  4. Number of participants with clinically significant alterations in vitals signs and abnormal laboratory parameters

    To assess the safety and tolerability of AZD4512 monotherapy or in combination in participants with R/R B-NHL

    Time frame: From the first dose up to and including 30 (+7) days after the last dose of study treatment , but prior to subsequent cancer therapy

Secondary outcomes

  1. Objective response rate (ORR)

    ORR, according to Lugano classification 2014, to evaluate the preliminary efficacy of AZD4512 monotherapy or in combination in participants with R/R B-NHL.

    Time frame: Up to 2 years

  2. Complete response (CR) rate

    CR rate, according to Lugano classification 2014, to evaluate the preliminary efficacy of AZD4512 monotherapy or in combination in participants with R/R B-NHL.

    Time frame: Up to 2 years

  3. Duration of response (DoR)

    DoR, according to Lugano classification 2014, to evaluate the preliminary efficacy of AZD4512 monotherapy or in combination in participants with R/R B-NHL.

    Time frame: Up to 2 years

  4. Progression-free survival (PFS)

    PFS, according to Lugano classification 2014, to evaluate the preliminary efficacy of AZD4512 monotherapy or in combination in participants with R/R B-NHL.

    Time frame: Up to 2 years

  5. Overall survival (OS)

    OS, defined as the time from the date of first dose until date of death, to evaluate the preliminary efficacy of AZD4512 monotherapy or in combination in participants with R/R B-NHL.

    Time frame: Up to 2 years

  6. Area Under plasma concentration-time Curve (AUC) of AZD4512, total antibody and total unconjugated warhead

    To characterize the AUC of AZD4512 as monotherapy or in combination in participants with R/R B-NHL

    Time frame: Up to 2 years

  7. Observed plasma (peak) drug concentration (Cmax) of AZD4512, total antibody and total unconjugated warhead

    To characterize the Cmax of AZD4512 as monotherapy or in combination in participants with R/R B-NHL

    Time frame: Up to 2 years

  8. Trough concentration (Ctrough) of AZD4512, total antibody and total unconjugated warhead

    To characterize the Ctrough of AZD4512 as monotherapy or in combination in participants with R/R B-NHL

    Time frame: Up to 2 years

  9. Half life of AZD4512, total antibody and total unconjugated warhead

    To characterize the Half life of AZD4512 as monotherapy or in combination in participants with R/R B-NHL

    Time frame: Up to 2 years

  10. Time to reach peak or maximum observed concentration (tmax) of AZD4512, total antibody and total unconjugated warhead

    To characterize the Tmax of AZD4512 as monotherapy or in combination in participants with R/R B-NHL

    Time frame: Up to 2 years

  11. Total clearance of AZD4512, total antibody and total unconjugated warhead

    To characterize the Total clearance of AZD4512 as monotherapy or in combination in participants with R/R B-NHL

    Time frame: Up to 2 years

  12. The number and percentage of participants who develop anti-drug antibodies (ADAs)

    To determine the immunogenicity of AZD4512 as monotherapy or in combination in participants with R/R B-NHL

    Time frame: Up to 2 years

07

Study locations

16 of 23 sites recruiting
  • Research Site
    Irvine, California 92618, United States
    Suspended

    Not enrolling at this site — choose another above.

  • Research Site
    Jacksonville, Florida 32224, United States
    Recruiting
  • Research Site
    Rochester, Minnesota 55905, United States
    Recruiting
  • Research Site
    New York, New York 10016, United States
    Suspended

    Not enrolling at this site — choose another above.

  • Research Site
    New York, New York 10021, United States
    Recruiting
  • Research Site
    Cleveland, Ohio 44195, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Myrtle Beach, South Carolina 29572, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Franklin, Tennessee 37067, United States
    Recruiting
  • Research Site
    Macquarie University, 2109, Australia
    Not yet recruiting
  • Research Site
    Melbourne, 3000, Australia
    Recruiting
  • Research Site
    Chengdu, 610041, China
    Not yet recruiting
  • Research Site
    Guangzhou, 510060, China
    Not yet recruiting
  • Research Site
    Bologna, 40138, Italy
    Recruiting
  • Research Site
    Milan, 20133, Italy
    Recruiting
  • Research Site
    Milan, 20141, Italy
    Recruiting
  • Research Site
    Bunkyō City, 113-8677, Japan
    Recruiting
  • Research Site
    Kōtoku, 135-8550, Japan
    Recruiting
  • Research Site
    Seoul, 03080, South Korea
    Recruiting
  • Research Site
    Seoul, 5505, South Korea
    Recruiting
  • Research Site
    Taichung, 40705, Taiwan
    Recruiting
  • Research Site
    Taipei, 106, Taiwan
    Recruiting
  • Research Site
    London, W1T 7HA, United Kingdom
    Recruiting
  • Research Site
    Newcastle upon Tyne, NE7 7DN, United Kingdom
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the European Federation of Pharmaceutical Industries and Associations (EFPIA) and the Pharmaceutical Research and Manufacturers of America (PhRMA) Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Jul 2028, 33 months after the start.

Of 94 phase 1/2 interventional studies under Lymphoma, B-Cell, half reached primary completion within 71 months of starting (the median), counting those still running; a quarter within 55 and three quarters within 96. This study's planned 33 months is below that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 2, 2026: primary completion Mar 2028 → Jul 2028 and completion Mar 2028 → Feb 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 24, 2025
First posted
Aug 14, 2025
StartActual
Sep 24, 2025
Primary completionEst.
Jul 4, 2028was Mar 2028
CompletionEst.
Feb 15, 2029was Mar 2028
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Mar 1, 2028→Jul 4, 2028
Nov 2, 2026
Study completion
Mar 1, 2028→Feb 15, 2029
Nov 2, 2026
Enrollment
91→164
Nov 2, 2026
Eligibility
6 criteria edited, 15 added, 2 removed
What changed in the criteria
  • EditedKeyCore Inclusion Criteria:
  • EditedAdditional criteria include measurable disease by Lugano 2014, Eastern Cooperative Oncology Group (ECOG) performance status ≤2, and adequate organ and bone marrow function (as specified by blood counts, cardiac ejection fraction, renal and hepatic parameters, and coagulation indices).
  • AddedModule 1 Monotherapy Inclusion criteria
  • RemovedPatients must have relapsed or refractory disease after at least two prior lines of systemic therapy and lack additional standard options with established benefit:
  • AddedPatients with LBCL must have relapsed or refractory disease after at least two prior lines of systemic therapy and lack additional standard options with established benefit. Additionally patients must have progressed after both anti CD20 and at least one systemic chemotherapy regimen, and have considered-or be ineligible for-CAR-T, T cell engager, and stem cell transplant modalities Participants with MCL must have previously received an anti-CD20 based therapy, and BTKi
  • AddedModule 2 Surovatamig Combination Inclusion criteria
  • AddedDocumented histologically confirmed diagnosis of LBCL as defined as: DLBCL ( not otherwise specified), Grade 3b FL, DLBCL/high grade B-cell lymphoma with MYC and BCL2 rearrangements, High grade B-cell lymphoma (not other specified), Primary mediastinal LBCL, T-cell/histiocyte-rich LBCL, Transformations of indolent B-cell lymphoma.
  • AddedParticipants who have received previous CD19-directed therapy must have locally assessed confirmation (after completion of the CD19-directed therapy) to demonstrate presence of CD19 expression by immunohistochemistry or flow cytometry.
  • EditedA)LBCLPatients must have relapsed or refractory disease after at least two prior lines of systemic therapy and lack additional standard options with established benefit. Additionally patients must have progressed after both anti-CD20 and at least one systemic chemotherapy regimen, and have considered-or be ineligible for-CAR-T, T cell engager, and stem cell transplant modalities.
  • RemovedMantle cell lymphoma (MCL) patients must have had anti-CD20 and Bruton's Tyrosine Kinase (BTK) inhibitor.
  • EditedKeyCore Exclusion criteriaCriteria
  • EditedPatients are excluded if they have a diagnosis of post-transplant lymphoproliferative disease, Richter's transformation, Burkitt's lymphoma, or chronic lymphocytic leukemia (CLL)/ Small lymphocytic lymphoma (SLL), Waldenstrom Macroglobulinemia/ Lymphoplasmacytic Lymphoma, or if they have active Central nervous system (Active CNS) involvement from their B-NHL. Exclusion also applies to those who have received Chimeric antigen receptorCAR-T (CAR-T), within 6 months or T cell engager therapies within 90 days prior to Cycle 1 Day 1 (C1D1), any investigational drug or other systemic anticancer therapies (except low-dose corticosteroids, ≤10mg prednisone/day) within 21 days or 5 half-lives, and curative radiation within 14 days (localized palliative radiotherapy is allowed).
  • EditedOther exclusions include: allogeneic Hematopoietic stem cell transplantation (HSCT) within 180 days (unless stable without active (graft-versus-host disease) GVHD for ≥2 months), autologous HSCT within 90 days (unless resolved toxicities), major surgery within 28 days, use of strong CYP3A inhibitors within 14 days or 5 half-lives before the dosing date, use of QTc-prolonging agents within 5 half-lives before the dosing date, or other malignancies within two years. Patients with unresolved ≥ Grade 2 AEs from prior therapy (except specified tolerable conditions), serious uncontrolled medical conditions, active infection within 14 days, or history/suspicion of significant interstitial lung diseaseILD/pneumonitis are also excluded.
  • AddedPrevious dosing with AZD4512
  • AddedModule 1 Exclusion Criteria Patients are excluded if they have a diagnosis of post transplant lymphoproliferative disease, Richter's transformation, Burkitt's lymphoma, CLL/SLL, Waldenstrom Macroglobulinemia/ Lymphoplasmacytic Lymphoma
  • AddedModule 2 Exclusion Criteria
  • AddedParticipants will be excluded if they have:
  • AddedClinically significant central nervous system (CNS) pathologies, including neurological, neurodegenerative, psychiatric, or other severe mental health conditions.
  • AddedActive or prior CNS involvement related to autoimmune disease.
  • AddedLeukemic presentation of non-Hodgkin lymphoma (NHL), with circulating malignant lymphoid cells in peripheral blood.
  • AddedA history of hemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS). • Prior Grade ≥3 cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS) following CAR T-cell or T-cell engager (TCE) therapy, or any unresolved CRS/ICANS.
  • AddedPrior exposure to surovatamig.
  • AddedDiagnosis of Richter's transformation
Nov 2, 2026
Interventions
Added Drug: Surovatamig. Arms added: Module 2: AZD4512 in combination with surovatamig dose escalation + backfills
Nov 2, 2026
Primary outcomes
2 edited, 2 description edited
What changed in the outcomes
  • EditedPercentage of participants with dose-limiting toxicities (DLTs) during the DLT periodTime frame: Up to 4 weeks
  • EditedFrequency of SAEs/AEs leading to discontinuation of AZD4512study treatmentTime frame: From the first dose up to and including 30 (+7) days after the last dose of study treatment , but prior to subsequent cancer therapy
  • DescriptionFrequency, duration, severity of Treatment-Emergent Adverse Events (TEAEs) and Treatment-Related Adverse Events (TRAEs) and Serious Adverse Events (SAEs): how it is measured was reworded
  • DescriptionNumber of participants with clinically significant alterations in vitals signs and abnormal laboratory parameters: how it is measured was reworded
Nov 2, 2026
Secondary outcomes
12 description edited
What changed in the outcomes
  • DescriptionArea Under plasma concentration-time Curve (AUC) of AZD4512, total antibody and total unconjugated warhead: how it is measured was reworded
  • DescriptionComplete response (CR) rate: how it is measured was reworded
  • DescriptionDuration of response (DoR): how it is measured was reworded
  • DescriptionHalf life of AZD4512, total antibody and total unconjugated warhead: how it is measured was reworded
  • DescriptionObjective response rate (ORR): how it is measured was reworded
  • DescriptionObserved plasma (peak) drug concentration (Cmax) of AZD4512, total antibody and total unconjugated warhead: how it is measured was reworded
  • DescriptionOverall survival (OS): how it is measured was reworded
  • DescriptionProgression-free survival (PFS): how it is measured was reworded
  • DescriptionThe number and percentage of participants who develop anti-drug antibodies (ADAs): how it is measured was reworded
  • DescriptionTime to reach peak or maximum observed concentration (tmax) of AZD4512, total antibody and total unconjugated warhead: how it is measured was reworded
  • DescriptionTotal clearance of AZD4512, total antibody and total unconjugated warhead: how it is measured was reworded
  • DescriptionTrough concentration (Ctrough) of AZD4512, total antibody and total unconjugated warhead: how it is measured was reworded
Nov 2, 2026
Show all 2 updates
  1. Nov 2, 2026
    Primary completion Mar 1, 2028→Jul 4, 2028
    Study completion Mar 1, 2028→Feb 15, 2029
    Enrollment 91→164
    Eligibility 6 criteria edited, 15 added, 2 removed
    What changed in the criteria
    • EditedKeyCore Inclusion Criteria:
    • EditedAdditional criteria include measurable disease by Lugano 2014, Eastern Cooperative Oncology Group (ECOG) performance status ≤2, and adequate organ and bone marrow function (as specified by blood counts, cardiac ejection fraction, renal and hepatic parameters, and coagulation indices).
    • AddedModule 1 Monotherapy Inclusion criteria
    • RemovedPatients must have relapsed or refractory disease after at least two prior lines of systemic therapy and lack additional standard options with established benefit:
    • AddedPatients with LBCL must have relapsed or refractory disease after at least two prior lines of systemic therapy and lack additional standard options with established benefit. Additionally patients must have progressed after both anti CD20 and at least one systemic chemotherapy regimen, and have considered-or be ineligible for-CAR-T, T cell engager, and stem cell transplant modalities Participants with MCL must have previously received an anti-CD20 based therapy, and BTKi
    • AddedModule 2 Surovatamig Combination Inclusion criteria
    • AddedDocumented histologically confirmed diagnosis of LBCL as defined as: DLBCL ( not otherwise specified), Grade 3b FL, DLBCL/high grade B-cell lymphoma with MYC and BCL2 rearrangements, High grade B-cell lymphoma (not other specified), Primary mediastinal LBCL, T-cell/histiocyte-rich LBCL, Transformations of indolent B-cell lymphoma.
    • AddedParticipants who have received previous CD19-directed therapy must have locally assessed confirmation (after completion of the CD19-directed therapy) to demonstrate presence of CD19 expression by immunohistochemistry or flow cytometry.
    • EditedA)LBCLPatients must have relapsed or refractory disease after at least two prior lines of systemic therapy and lack additional standard options with established benefit. Additionally patients must have progressed after both anti-CD20 and at least one systemic chemotherapy regimen, and have considered-or be ineligible for-CAR-T, T cell engager, and stem cell transplant modalities.
    • RemovedMantle cell lymphoma (MCL) patients must have had anti-CD20 and Bruton's Tyrosine Kinase (BTK) inhibitor.
    • EditedKeyCore Exclusion criteriaCriteria
    • EditedPatients are excluded if they have a diagnosis of post-transplant lymphoproliferative disease, Richter's transformation, Burkitt's lymphoma, or chronic lymphocytic leukemia (CLL)/ Small lymphocytic lymphoma (SLL), Waldenstrom Macroglobulinemia/ Lymphoplasmacytic Lymphoma, or if they have active Central nervous system (Active CNS) involvement from their B-NHL. Exclusion also applies to those who have received Chimeric antigen receptorCAR-T (CAR-T), within 6 months or T cell engager therapies within 90 days prior to Cycle 1 Day 1 (C1D1), any investigational drug or other systemic anticancer therapies (except low-dose corticosteroids, ≤10mg prednisone/day) within 21 days or 5 half-lives, and curative radiation within 14 days (localized palliative radiotherapy is allowed).
    • EditedOther exclusions include: allogeneic Hematopoietic stem cell transplantation (HSCT) within 180 days (unless stable without active (graft-versus-host disease) GVHD for ≥2 months), autologous HSCT within 90 days (unless resolved toxicities), major surgery within 28 days, use of strong CYP3A inhibitors within 14 days or 5 half-lives before the dosing date, use of QTc-prolonging agents within 5 half-lives before the dosing date, or other malignancies within two years. Patients with unresolved ≥ Grade 2 AEs from prior therapy (except specified tolerable conditions), serious uncontrolled medical conditions, active infection within 14 days, or history/suspicion of significant interstitial lung diseaseILD/pneumonitis are also excluded.
    • AddedPrevious dosing with AZD4512
    • AddedModule 1 Exclusion Criteria Patients are excluded if they have a diagnosis of post transplant lymphoproliferative disease, Richter's transformation, Burkitt's lymphoma, CLL/SLL, Waldenstrom Macroglobulinemia/ Lymphoplasmacytic Lymphoma
    • AddedModule 2 Exclusion Criteria
    • AddedParticipants will be excluded if they have:
    • AddedClinically significant central nervous system (CNS) pathologies, including neurological, neurodegenerative, psychiatric, or other severe mental health conditions.
    • AddedActive or prior CNS involvement related to autoimmune disease.
    • AddedLeukemic presentation of non-Hodgkin lymphoma (NHL), with circulating malignant lymphoid cells in peripheral blood.
    • AddedA history of hemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS). • Prior Grade ≥3 cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS) following CAR T-cell or T-cell engager (TCE) therapy, or any unresolved CRS/ICANS.
    • AddedPrior exposure to surovatamig.
    • AddedDiagnosis of Richter's transformation
    Primary outcomes 2 edited, 2 description edited
    What changed in the outcomes
    • EditedPercentage of participants with dose-limiting toxicities (DLTs) during the DLT periodTime frame: Up to 4 weeks
    • EditedFrequency of SAEs/AEs leading to discontinuation of AZD4512study treatmentTime frame: From the first dose up to and including 30 (+7) days after the last dose of study treatment , but prior to subsequent cancer therapy
    • DescriptionFrequency, duration, severity of Treatment-Emergent Adverse Events (TEAEs) and Treatment-Related Adverse Events (TRAEs) and Serious Adverse Events (SAEs): how it is measured was reworded
    • DescriptionNumber of participants with clinically significant alterations in vitals signs and abnormal laboratory parameters: how it is measured was reworded
    Secondary outcomes 12 description edited
    What changed in the outcomes
    • DescriptionArea Under plasma concentration-time Curve (AUC) of AZD4512, total antibody and total unconjugated warhead: how it is measured was reworded
    • DescriptionComplete response (CR) rate: how it is measured was reworded
    • DescriptionDuration of response (DoR): how it is measured was reworded
    • DescriptionHalf life of AZD4512, total antibody and total unconjugated warhead: how it is measured was reworded
    • DescriptionObjective response rate (ORR): how it is measured was reworded
    • DescriptionObserved plasma (peak) drug concentration (Cmax) of AZD4512, total antibody and total unconjugated warhead: how it is measured was reworded
    • DescriptionOverall survival (OS): how it is measured was reworded
    • DescriptionProgression-free survival (PFS): how it is measured was reworded
    • DescriptionThe number and percentage of participants who develop anti-drug antibodies (ADAs): how it is measured was reworded
    • DescriptionTime to reach peak or maximum observed concentration (tmax) of AZD4512, total antibody and total unconjugated warhead: how it is measured was reworded
    • DescriptionTotal clearance of AZD4512, total antibody and total unconjugated warhead: how it is measured was reworded
    • DescriptionTrough concentration (Ctrough) of AZD4512, total antibody and total unconjugated warhead: how it is measured was reworded
    Interventions Added Drug: Surovatamig. Arms added: Module 2: AZD4512 in combination with surovatamig dose escalation + backfills
    + 2 other changes: description and design details
  2. Oct 14, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07123454
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Aug 14, 2025
Start date
Sep 24, 2025
Primary completion
Jul 4, 2028 (estimated)
Completion
Feb 15, 2029 (estimated)
Last update
Nov 2, 2026

Study contacts

AstraZeneca Clinical Study Information Center
Contact
information.center@astrazeneca.com
1-877-240-9479

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion